BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading Volume – Should You Buy?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares saw unusually-high trading volume on Friday . Approximately 3,621,276 shares changed hands during mid-day trading, an increase of 15% from the previous session’s volume of 3,159,396 shares.The stock last traded at $76.29 and had previously closed at $76.26.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Lower near-term interest cost and extended maturity — the new notes carry 0.75% interest vs. the company’s 2.50% 2027 notes and push maturity to 2033, which should reduce cash interest expense and extend refinancing risk, improving balance-sheet flexibility. BridgeBio Prices Offering (GlobeNewswire)
• Positive Sentiment: Share repurchase tied to the deal reduces near-term float and may support the stock while also pushing the effective conversion price higher (helps limit immediate dilution). Management is using ~$82.5M cash to repurchase ~1.1M shares concurrently with the note pricing. QuiverQuant deal summary
• Positive Sentiment: Analyst/Wall Street tone is constructive — brokerages give a consensus “Moderate Buy” and recent price targets (median ≈ $86) remain above current levels, which supports investor confidence. Consensus Recommendation (AmericanBankingNews)
• Neutral Sentiment: Conversion terms limit near-term dilution — the initial conversion price is ~45% above the last trade, and conversions are restricted until certain conditions/periods (convertibility becomes more open closer to maturity), so dilution risk is muted in the short run. Finanznachrichten pricing details
• Negative Sentiment: Increased leverage and potential future dilution — the company is issuing incremental convertible debt (structurally junior to some obligations) and conversion or future redemptions could dilute equity holders over time; the offering is private (Rule 144A) and not registered. QuiverQuant private offering note
• Negative Sentiment: Insider selling and institutional adjustments noted in public data could weigh on sentiment — recent disclosures show sizable insider sales and some large institutional rebalances, which investors may view as a cautionary signal. QuiverQuant insider & institutional data

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Morgan Stanley assumed coverage on shares of BridgeBio Pharma in a research note on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 target price for the company. The Goldman Sachs Group upped their price objective on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. TD Cowen raised their price objective on BridgeBio Pharma from $60.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Leerink Partners boosted their target price on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Finally, Sanford C. Bernstein assumed coverage on BridgeBio Pharma in a report on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price target for the company. Twenty-two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $78.85.

BridgeBio Pharma Stock Performance

The company has a market capitalization of $14.70 billion, a P/E ratio of -18.24 and a beta of 1.17. The firm’s 50 day moving average price is $72.97 and its two-hundred day moving average price is $59.01.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The company had revenue of $120.70 million for the quarter, compared to analyst estimates of $107.71 million. During the same period last year, the firm earned ($0.86) EPS. The company’s revenue was up 4318.0% compared to the same quarter last year. Analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Ronald J. Daniels sold 61,031 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $63.72, for a total value of $3,888,895.32. Following the completion of the transaction, the director directly owned 16,991 shares in the company, valued at $1,082,666.52. This trade represents a 78.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Andrew Lo sold 55,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total value of $3,612,950.00. Following the sale, the director owned 50,583 shares in the company, valued at approximately $3,322,797.27. This represents a 52.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 587,215 shares of company stock worth $39,569,101 over the last three months. Company insiders own 18.20% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter worth about $643,000. WINTON GROUP Ltd bought a new position in BridgeBio Pharma in the 2nd quarter valued at about $3,856,000. Moss Adams Wealth Advisors LLC lifted its position in BridgeBio Pharma by 49.2% during the second quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company’s stock worth $1,044,000 after acquiring an additional 7,970 shares during the last quarter. Bosun Asset Management LLC lifted its position in BridgeBio Pharma by 119.7% during the second quarter. Bosun Asset Management LLC now owns 26,154 shares of the company’s stock worth $1,129,000 after acquiring an additional 14,250 shares during the last quarter. Finally, Bryce Point Capital LLC bought a new stake in shares of BridgeBio Pharma during the second quarter worth approximately $598,000. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.